(The H4-Index of Drugs is 56. The table below lists those papers that are above that threshold based on CrossRef citation counts [max. 250 papers]. The publications cover those that have been published in the past four years, i.e., from 2020-04-01 to 2024-04-01.)
Prevention and Treatment of Monkeypox313
BNT162b2 mRNA COVID-19 Vaccine: First Approval224
Pharmaco-Immunomodulatory Therapy in COVID-19191
Inhibiting CDK4/6 in Breast Cancer with Palbociclib, Ribociclib, and Abemaciclib: Similarities and Differences174
Inclisiran: First Approval170
Lumasiran: First Approval167
The Antifungal Pipeline: Fosmanogepix, Ibrexafungerp, Olorofim, Opelconazole, and Rezafungin167
Remdesivir: First Approval166
The Epidemiology and Pathogenesis and Treatment of Pseudomonas aeruginosa Infections: An Update164
Nirmatrelvir Plus Ritonavir: First Approval156
Casimersen: First Approval135
Sacituzumab Govitecan: First Approval134
Pemigatinib: First Approval127
Aducanumab: First Approval114
Viltolarsen: First Approval114
Sotorasib: First Approval112
Risdiplam: First Approval99
Acute Pancreatitis: Diagnosis and Treatment92
Abuse and Misuse of Pregabalin and Gabapentin: A Systematic Review Update92
New Treatment Strategies for Metastatic Pancreatic Ductal Adenocarcinoma92
TRPV1-Targeted Drugs in Development for Human Pain Conditions91
Setmelanotide: First Approval91
Efficacy and Safety of RBX2660 in PUNCH CD3, a Phase III, Randomized, Double-Blind, Placebo-Controlled Trial with a Bayesian Primary Analysis for the Prevention of Recurrent Clostridioides difficile I90
Managing Diabetic Foot Ulcers: Pharmacotherapy for Wound Healing88
Selpercatinib: First Approval86
Targeting Sphingosine-1-Phosphate Signaling in Immune-Mediated Diseases: Beyond Multiple Sclerosis85
Bulevirtide: First Approval84
Is Acetylsalicylic Acid a Safe and Potentially Useful Choice for Adult Patients with COVID-19 ?83
Belantamab Mafodotin: First Approval83
Remimazolam: First Approval83
Sphingosine 1-phosphate Receptor Modulator Therapy for Multiple Sclerosis: Differential Downstream Receptor Signalling and Clinical Profile Effects80
Pharmacokinetics and Pharmacodynamics of Posaconazole79
Orelabrutinib: First Approval79
Inhaled Liposomal Antimicrobial Delivery in Lung Infections73
New and Emerging Systemic Treatments for Atopic Dermatitis72
Ozanimod: First Approval72
Nivolumab Plus Relatlimab: First Approval72
Targeting the PI3K/AKT/mTOR Pathway in Hormone-Positive Breast Cancer71
Immune Therapy, or Antiviral Therapy, or Both for COVID-19: A Systematic Review69
REGN-EB3: First Approval68
Selumetinib: First Approval67
Tirabrutinib: First Approval67
ACE Inhibitor Benefit to Kidney and Cardiovascular Outcomes for Patients with Non-Dialysis Chronic Kidney Disease Stages 3–5: A Network Meta-Analysis of Randomised Clinical Trials66
Fabry Disease: The Current Treatment Landscape66
Lonafarnib: First Approval66
Amivantamab: First Approval65
Pralsetinib: First Approval63
Decitabine/Cedazuridine: First Approval62
Capmatinib: First Approval62
HIV-1 Integrase Inhibitors: A Comparative Review of Efficacy and Safety61
Savolitinib: First Approval60
Belzutifan: First Approval60
Inebilizumab: First Approval60
MicroRNA Mimics or Inhibitors as Antiviral Therapeutic Approaches Against COVID-1958
Bempedoic Acid: First Approval57
Remimazolam: A Review in Procedural Sedation56
Updated Overall Survival in a Randomized Study Comparing Dacomitinib with Gefitinib as First-Line Treatment in Patients with Advanced Non-Small-Cell Lung Cancer and EGFR-Activating Mutations56
Novel Agents for the Pharmacological Treatment of Alcohol Use Disorder56